www.TheFinancialMarketingGroup.com
Followers | 59 |
Posts | 2,197 |
Boards Moderated | 4 |
Alias Born | 04/28/2019 |
Twitter Profile: | Temporarily Unavailable |
Follow on Twitter: | Follow @ Temporarily Unavailable |
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$MYND Tomorrow could be a big day, after hours action again
On Thursday the company announced that certain investors have agreed to purchase approximately $2.8 million of the Company’s common stock in a registered direct offering. The stock had a run but the weakness in the market it sonon pulled back. When we get a good day in the market keep a watch on this stock for a monster move on high volume .
The Company entered into a securities purchase agreement with the investors pursuant to which the Company agreed to sell 2,776,491 shares of its common stock at a per share price of $1.02. The closing of the registered direct offering is expected to take place on or about May 28, 2019, subject to the satisfaction of customary closing conditions.
Average Analysts Price Target $4
Average recommendation Buy
$qrvo Selling could be coming to a end, volume decline today
The volume profile in Qrvo is very ugly, massive sell candles with over 100% extra volume each day for the last week,but can we it as capitulation and a sign to step back in to the long side. Given the exposure that NASDAQ:QRVO has to China it is a risky move. We see the $54 area been tested once again, on confirmation of it holding then it is a good time to get a reversal trade. The RSI is very low at 22 but it can go much lower as the NASDAQ:SOX could possible drop below the 200ma, bringing more selling.
$qrvo Selling could be coming to a end, volume decline today
The volume profile in Qrvo is very ugly, massive sell candles with over 100% extra volume each day for the last week,but can we it as capitulation and a sign to step back in to the long side. Given the exposure that NASDAQ:QRVO has to China it is a risky move. We see the $54 area been tested once again, on confirmation of it holding then it is a good time to get a reversal trade. The RSI is very low at 22 but it can go much lower as the NASDAQ:SOX could possible drop below the 200ma, bringing more selling.
$NVCN BULL RUN GETTING READY ON POSITIVE ANGINA TREATMENT
Neovasc a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced on wednesday the 22nd may that the International Journal of Cardiology has published a peer reviewed article regarding long term sustained efficacy and safety of the Reducer therapy in 50 patients suffering from refractory disabling angina. The title of the article is: "Safety and efficacy of Coronary Sinus Reducer implantation at 2-year follow-up."
This study shows us that the Reducer has a sustained therapeutic effect at two years across a large patient population. In addition, we believe this study provides valuable long-term safety data that further supports cardiologists use of the Reducer as a therapeutic option for patients suffering from refractory angina," commented Prof. Shmuel Banai, Medical Director of Neovasc . "This data supports our belief that the Reducer offers refractory angina patients a safe and effective treatment option, filling a void in a market where there are currently limited therapeutic options."
The stock very well have a 100% move in the coming days so don't be caught napping. Currently sitting below resistance at $.76 a break above $.9 opens the door to the bulls.
AVERAGE TARGET PRICE $2.51
AVERAGE RECOMMENDATION OVERWEIGHT
$NVCN BULL RUN GETTING READY ON POSITIVE ANGINA TREATMENT
Neovasc a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced on wednesday the 22nd may that the International Journal of Cardiology has published a peer reviewed article regarding long term sustained efficacy and safety of the Reducer therapy in 50 patients suffering from refractory disabling angina. The title of the article is: "Safety and efficacy of Coronary Sinus Reducer implantation at 2-year follow-up."
This study shows us that the Reducer has a sustained therapeutic effect at two years across a large patient population. In addition, we believe this study provides valuable long-term safety data that further supports cardiologists use of the Reducer as a therapeutic option for patients suffering from refractory angina," commented Prof. Shmuel Banai, Medical Director of Neovasc . "This data supports our belief that the Reducer offers refractory angina patients a safe and effective treatment option, filling a void in a market where there are currently limited therapeutic options."
The stock very well have a 100% move in the coming days so don't be caught napping. Currently sitting below resistance at $.76 a break above $.9 opens the door to the bulls.
AVERAGE TARGET PRICE $2.51
AVERAGE RECOMMENDATION OVERWEIGHT
$PRTO CONTINUATION TODAY IN PROTEON, UP PRE MARKET
NASDAQ:PRTO IS SETTING UP FOR A MONSTER RALLY IN THE COMING DAYS, ALREADY UP 50% THIS WEEK A BREAK ABOVE $.70 COULD RESULT IN A 150% MOVE. lARGE GAP FILL EXIST BELWO THIS LEVEL WITH $3.30 AS THE TARGET GIVING A +300% MOVE. kEEP ON THE WATCHLIST FOR BREAK ABOVE RESISTANCE AT $.70
Short Interest 13%
Analysts price target $5
Analysts recommendation HOLD
$PRTO CONTINUATION TODAY IN PROTEON, UP PRE MARKET
NASDAQ:PRTO IS SETTING UP FOR A MONSTER RALLY IN THE COMING DAYS, ALREADY UP 50% THIS WEEK A BREAK ABOVE $.70 COULD RESULT IN A 150% MOVE. lARGE GAP FILL EXIST BELWO THIS LEVEL WITH $3.30 AS THE TARGET GIVING A +300% MOVE. kEEP ON THE WATCHLIST FOR BREAK ABOVE RESISTANCE AT $.70
Short Interest 13%
Analysts price target $5
Analysts recommendation HOLD
$IOVA SETTING UP FOR STRONG MOVE TOMORROW, FDA REVIEW
*****CONTINUATION LOOKS ON THE CARDS TOMORROW, STRONG GAINS THE AFTER HOURS ONCE AGAIN ON GOOV VOLUME . CURRENTLY ON RESISTANCE AT $18 A BREAK COULD BE VERY REWARDING.
***********NEWS FLOW*********
The FDA designates Iovance Biotherapeutics' (NASDAQ:IOVA) LN-145 a Breakthrough Therapy for the treatment of recurrent, metastatic, or persistent cervical cancer that has progressed on or after chemotherapy.
Breakthrough Therapy status provides for more intensive guidance from the FDA on development, the involvement of more senior agency personnel and a rolling review of the marketing application
$IOVA SETTING UP FOR STRONG MOVE TOMORROW, FDA REVIEW
*****CONTINUATION LOOKS ON THE CARDS TOMORROW, STRONG GAINS THE AFTER HOURS ONCE AGAIN ON GOOV VOLUME . CURRENTLY ON RESISTANCE AT $18 A BREAK COULD BE VERY REWARDING.
***********NEWS FLOW*********
The FDA designates Iovance Biotherapeutics' (NASDAQ:IOVA) LN-145 a Breakthrough Therapy for the treatment of recurrent, metastatic, or persistent cervical cancer that has progressed on or after chemotherapy.
Breakthrough Therapy status provides for more intensive guidance from the FDA on development, the involvement of more senior agency personnel and a rolling review of the marketing application
$CTRP Great setup into earnings this evening. Bullish
The stock has had a lovely bounce after filling the gap from post earnings in FEb 19, and is now set for a new run higher with $39, and $42 as conservative targets. Indicators have also reset after hitting oversold territory, combined with renewed buyer interest .
Average Price Target $44
Average recommendation Overweight
$CTRP Great setup into earnings this evening. Bullish
The stock has had a lovely bounce after filling the gap from post earnings in FEb 19, and is now set for a new run higher with $39, and $42 as conservative targets. Indicators have also reset after hitting oversold territory, combined with renewed buyer interest .
Average Price Target $44
Average recommendation Overweight
$NVUS BREAKOUT IMMINENT IN Novus Therapeutics, VOLUME SPIKES
****Alerts are set for a break above the 12ma which has been blocking the stock action for some days, if it can break this level, it's off to the races for some major gains. Volume has spiked today but that it is just for starters, don't miss out on the next big move. ***************
NOVAS THERAPEUTICS INC, DEVELOPS AND SPECIALISES IN DRUGS FOR THE TREATMENT OF EAR, NOSE AND THROAT CONDITIONS.
AVERAGE PRICE TARGET $8.75
AVERAGE ANALYSTS RECOMMENDATION BUY
$NVUS BREAKOUT IMMINENT IN Novus Therapeutics, VOLUME SPIKES
****Alerts are set for a break above the 12ma which has been blocking the stock action for some days, if it can break this level, it's off to the races for some major gains. Volume has spiked today but that it is just for starters, don't miss out on the next big move. ***************
NOVAS THERAPEUTICS INC, DEVELOPS AND SPECIALISES IN DRUGS FOR THE TREATMENT OF EAR, NOSE AND THROAT CONDITIONS.
AVERAGE PRICE TARGET $8.75
AVERAGE ANALYSTS RECOMMENDATION BUY
$BBY IS BEST BUY REALLY A BEST BUY NOW, PRE EARNINGS ?
RETAIL HAS BEEN A NESS THIS WEEK WITH SOME REAL WIDOWMAKER DECLINES IN STOCKS, NYSE:TGT AHS BEEN THE EXCEPTION AND AS NYSE:BBY IS REPORTING TOMORROW MORNING INTO A NEGATIVE MARKET AND A NEGATIVE SECTOR, IT IS A STAY CLEAR FOR THE LONGS SIDE. THE STOCK HAS LOST SOME STEAM AND DESPITE BUYING VOLUME CONTINUING INTO THE REPORT, IT IS OUR OPINION A RISK NOT WORTH TAKING.
AVERAGE ANALYSTS ESTIMATE $76.91
AVERAGE RECOMMENDATION OVERWEIGHT
$BBY IS BEST BUY REALLY A BEST BUY NOW, PRE EARNINGS ?
RETAIL HAS BEEN A NESS THIS WEEK WITH SOME REAL WIDOWMAKER DECLINES IN STOCKS, NYSE:TGT AHS BEEN THE EXCEPTION AND AS NYSE:BBY IS REPORTING TOMORROW MORNING INTO A NEGATIVE MARKET AND A NEGATIVE SECTOR, IT IS A STAY CLEAR FOR THE LONGS SIDE. THE STOCK HAS LOST SOME STEAM AND DESPITE BUYING VOLUME CONTINUING INTO THE REPORT, IT IS OUR OPINION A RISK NOT WORTH TAKING.
AVERAGE ANALYSTS ESTIMATE $76.91
AVERAGE RECOMMENDATION OVERWEIGHT
$CPRT Mixed signals going into earnings today.
Copart is a very strong company with financial fundamentals, as earnings approach we are a little worried that the stock is starting to get tired and losing momentum. Indicators are all quite bearish and a break of trend could result in quite a sizeable correction, on the other hand positive results could aid the break above resistance and avoid the dreaded double top .
We have included on the chart 2 possible trades to cover either scenario, our bias is to the bearish side due only to the chart techinaly.
Average Analysts price target $61.44
Average Analysts recommendation Hold
$CPRT Mixed signals going into earnings today.
Copart is a very strong company with financial fundamentals, as earnings approach we are a little worried that the stock is starting to get tired and losing momentum. Indicators are all quite bearish and a break of trend could result in quite a sizeable correction, on the other hand positive results could aid the break above resistance and avoid the dreaded double top .
We have included on the chart 2 possible trades to cover either scenario, our bias is to the bearish side due only to the chart techinaly.
Average Analysts price target $61.44
Average Analysts recommendation Hold
$CPRT Mixed signals going into earnings today.
Copart is a very strong company with financial fundamentals, as earnings approach we are a little worried that the stock is starting to get tired and losing momentum. Indicators are all quite bearish and a break of trend could result in quite a sizeable correction, on the other hand positive results could aid the break above resistance and avoid the dreaded double top .
We have included on the chart 2 possible trades to cover either scenario, our bias is to the bearish side due only to the chart techinaly.
Average Analysts price target $61.44
Average Analysts recommendation Hold
$TNXP looks ready to breakout big today. This low-float Nasdaq..
TNXP looks ready to breakout big today. This low-float Nasdaq listed company could cure PSTD!
========================
TNXP (Tonix Pharmaceuticals Holding Corp.)
Alert Price: $1.70
Float: 4.74M
Chart Analysis
Roth Capital Price Target: $4.00
Investor Presentation
Company Website | Recent News
========================
Members,
We ask that you give your full attention to our new low-float Nasdaq listed alert TNXP (Tonix Pharmaceuticals Holding Corp.).
TNXP is a clinical-stage biopharmaceutical company focused on discovering and developing pharmaceutical products to treat psychiatric and pain conditions, and biological products to improve biodefense through potential medical counter-measures. Tonix’s lead program is for the development of Tonmya** (TNX-102 SL), which is in Phase 3 development as a bedtime treatment for PTSD.
PTSD is a serious chronic psychiatric illness defined as a maladaptive prolonged stress response which occurs after experiencing severely injurious traumatic event(s). While initially recognized as a stress response to military combat ('shell shock') it is now known that many civilians exposed to life-threatening events, sexual assault, natural disasters or accidents, can develop PTSD.
According to the latest report published by Credence Research, Inc. the global post-traumatic stress disorder therapeutics market is projected to reach US $10.679M by 2026, expanding at a CAGR of 4.5% from 2018 to 2026.
TNXP Has the Potential to Be the Biggest Gainer On the Nasdaq
With its low-float of 4.74M, TNXP is no stranger to massive single-day run-ups.
Take a look at these past single-session gains:
3/14 $2.58 to $3.24 for gains of +25.58%
3/11 $2.80 to $4.12 for gains of +47.14%
3/8 $2.14 to $4.20 for gains of +96.26%
12/7 $3.15 to $7.24 for gains of +129.84%
TNXP also has several bullish catalysts on the horizon:
Chart has recently formed a "Golden Cross" which generally signals an uptrend.
Roth Capital analyst Scott Henry upgraded TNXP from Neutral to Buy with a price target of $4.00.
The Company will be presenting pharmacokinetic analyses of TNX-102 SL* in a poster at the American Society of Clinical Psychopharmacology (ASCP) 2019 Annual Meeting.
Research has shown that PSTD treatment is not just for soldiers: Civilians with PTSD struggle to find effective therapy
About Tonix Pharmaceuticals Holding Corp.
Tonix is a clinical-stage biopharmaceutical company focused on discovering and developing pharmaceutical products to treat psychiatric and pain conditions, and biological products to improve biodefense through potential medical counter-measures. Tonix’s lead program is for the development of Tonmya** (TNX-102 SL), which is in Phase 3 development as a bedtime treatment for PTSD. Tonix is also developing TNX-102 SL as a bedtime treatment for fibromyalgia and agitation in Alzheimer’s disease under separate INDs to support potential pivotal efficacy studies. The fibromyalgia program is in Phase 3 development and the agitation in Alzheimer’s program is Phase 2 ready. The agitation in Alzheimer’s disease IND has been designated a Fast Track development program by the FDA. TNX-601 (tianeptine oxalate) is in the pre-IND application stage, also for the treatment of PTSD but by a different mechanism from TNX-102 SL and designed for daytime dosing. TNX-601 is also in development for a potential indication - neurocognitive dysfunction associated with corticosteroid use. A Phase 1 clinical formulation selection pharmacokinetic study of TNX-601 will be conducted outside of the U.S. in 2019. Tonix’s lead biologic candidate, TNX-801, is a potential smallpox-preventing vaccine based on a live synthetic version of horsepox virus, currently in the pre-IND application stage.
* TNX-102 SL (cyclobenzaprine HCl sublingual tablets) is an investigational new drug and has not been approved for any indication.
**Tonmya has been conditionally accepted by the U.S. Food and Drug Administration (FDA) as the proposed trade name for TNX-102 SL for the treatment of PTSD.
This press release and further information about Tonix can be found at http://www.tonixpharma.com.
Company Highlights:
Phase 3 development of new bedtime treatment for PTSD, including military related PTSD
Major unmet need; ~12 million Americans annually
Benefited from FDA 505(b)(2) NDA approval requirement
Complimentary day-time PTSD treatment in development
Leverages development expertise in PTSD, i.e., regulatory, trial recruitment and execution
Fibromyalgia bedtime treatment in development
New Phase 3 study design features discussed with FDA (April 2019 FDA Meeting Minutes)
TNX-102 SL 5.6 mg (twice the dose previously studied in FM Phase 2/3 trials) will be studied in Phase 3 to support the indication
New indication in development for agitation in Alzheimer’s Disease
Unmet medical need, no approved drug available
Fast Track Phase 2/3 ready program
Innovative vaccine in development to prevent Smallpox
Opportunity to supply stockpiling requirement; short development path
Studies in mice suggest improved safety profile
Recently Completed Milestones
July 2018 Completed P301/HONOR study interim analysis - result did not support study continuation but strengthened new Phase 3 study
August 2018 Presentation of P301/HONOR study results at Military Health System Scientific Symposium
October 2018 Met with FDA and received preliminary agreement on the design of new Phase 3 study of Tonmya for PTSD (P302/RECOVERY study)
November 2018 Received FDA minutes confirming agreement on the design of P302/RECOVERY study
March 2019 Met with FDA to discuss new FM Phase 3 study design using TNX-102 SL 5.6 mg
March 2019 P302/RECOVERY study initiated
April 2019 Received FDA formal minutes with clear guidance and support on new Phase 3 FM study
Upcoming Milestones
Second Half 2019 Preliminary human pharmacokinetic and safety data (non-IND study) from selected TNX-601 (tianeptine oxalate) formulation expected
First Half 2020 Topline data from P302/RECOVERY study expected
Market Outlook
Globally, the vast majority of people (~70%) will experience or witness one or more life-threatening traumatic events in their life-time. For many, the response to an isolated traumatic event will dissipate over days or a few weeks and have little or no long-term consequences.
For some individuals, however, the response to trauma will become chronic, lasting for more than one month and persisting for years, and, in many cases, decades. These individuals are considered to have PTSD and will experience psychiatric symptoms (flashbacks, intense anxiety and avoidance, emotional numbness, intense guilt or worry, agitation, sleep disturbances), and as a consequence, experience impaired social functioning, occupational disability, and an overall poor quality of life. PTSD is also characterized by overall high utilization of healthcare services, adding to the significant economic burden from the condition.
How prevalent is PTSD?
PTSD is a global problem, with the lifetime prevalence of PTSD estimated to be 3.9%, or affecting an estimated 200-300 million individuals, on a global basis.
Based on U.S. 12-month prevalence rates,1,2 it is estimated that about 11.0 million American adults suffer from DSM-5-defined PTSD in a given year. Similar to other psychiatric disorders, only approximately half of these individuals will seek treatment at some point in the course of the disease, and of these, approximately 40% (~1.8 million) will be formally diagnosed with PTSD in any given year. Lack of awareness, the negative stigma associated with PTSD (like other mental disorders), as well as the limitations of existing treatment options, may be addressed by increased societal awareness and acceptance as well as the introduction of new therapeutic options.
Technical Analysis
As we stated above, with its low-float of 4.74M, TNXP is no stranger to massive single-day run-ups.
TNXP's chart has recently formed a "Golden Cross" which generally signals an uptrend.
We've done our very own chart analysis, and see the potential for a move of over +27%!
The Bottom Line
We are extremely bullish on TNXP .
Based on our research we believe that this could be the biggest single-day gainer on the Nasdaq today.
That being said, we ask that you start your research on TNXP immediately and consider building a position this morning at 9:30AM EST
(*Remember to use a Stop-Loss Order or basic Limit Order to protect your gains, as well as limit possible losses.)
Best Regards,
The TopMarketGainers Team
Don't Miss Our Next Huge Winner...
Text 'GAINS' to '67076'
to have our Trade Alerts
Delivered Direct
to your Cell Phone.
(There is no charge.
Msg&data rates may apply.)
DISCLAIMER
This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned herewithin, nor intends to buy any in the future.
MJ Capital’s business model is to receive financial compensation to promote public companies. We have NOTbeen compensated to conduct investor relations advertising and marketing for TNXP . Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
$TNXP looks ready to breakout big today. This low-float Nasdaq..
TNXP looks ready to breakout big today. This low-float Nasdaq listed company could cure PSTD!
========================
TNXP (Tonix Pharmaceuticals Holding Corp.)
Alert Price: $1.70
Float: 4.74M
Chart Analysis
Roth Capital Price Target: $4.00
Investor Presentation
Company Website | Recent News
========================
Members,
We ask that you give your full attention to our new low-float Nasdaq listed alert TNXP (Tonix Pharmaceuticals Holding Corp.).
TNXP is a clinical-stage biopharmaceutical company focused on discovering and developing pharmaceutical products to treat psychiatric and pain conditions, and biological products to improve biodefense through potential medical counter-measures. Tonix’s lead program is for the development of Tonmya** (TNX-102 SL), which is in Phase 3 development as a bedtime treatment for PTSD.
PTSD is a serious chronic psychiatric illness defined as a maladaptive prolonged stress response which occurs after experiencing severely injurious traumatic event(s). While initially recognized as a stress response to military combat ('shell shock') it is now known that many civilians exposed to life-threatening events, sexual assault, natural disasters or accidents, can develop PTSD.
According to the latest report published by Credence Research, Inc. the global post-traumatic stress disorder therapeutics market is projected to reach US $10.679M by 2026, expanding at a CAGR of 4.5% from 2018 to 2026.
TNXP Has the Potential to Be the Biggest Gainer On the Nasdaq
With its low-float of 4.74M, TNXP is no stranger to massive single-day run-ups.
Take a look at these past single-session gains:
3/14 $2.58 to $3.24 for gains of +25.58%
3/11 $2.80 to $4.12 for gains of +47.14%
3/8 $2.14 to $4.20 for gains of +96.26%
12/7 $3.15 to $7.24 for gains of +129.84%
TNXP also has several bullish catalysts on the horizon:
Chart has recently formed a "Golden Cross" which generally signals an uptrend.
Roth Capital analyst Scott Henry upgraded TNXP from Neutral to Buy with a price target of $4.00.
The Company will be presenting pharmacokinetic analyses of TNX-102 SL* in a poster at the American Society of Clinical Psychopharmacology (ASCP) 2019 Annual Meeting.
Research has shown that PSTD treatment is not just for soldiers: Civilians with PTSD struggle to find effective therapy
About Tonix Pharmaceuticals Holding Corp.
Tonix is a clinical-stage biopharmaceutical company focused on discovering and developing pharmaceutical products to treat psychiatric and pain conditions, and biological products to improve biodefense through potential medical counter-measures. Tonix’s lead program is for the development of Tonmya** (TNX-102 SL), which is in Phase 3 development as a bedtime treatment for PTSD. Tonix is also developing TNX-102 SL as a bedtime treatment for fibromyalgia and agitation in Alzheimer’s disease under separate INDs to support potential pivotal efficacy studies. The fibromyalgia program is in Phase 3 development and the agitation in Alzheimer’s program is Phase 2 ready. The agitation in Alzheimer’s disease IND has been designated a Fast Track development program by the FDA. TNX-601 (tianeptine oxalate) is in the pre-IND application stage, also for the treatment of PTSD but by a different mechanism from TNX-102 SL and designed for daytime dosing. TNX-601 is also in development for a potential indication - neurocognitive dysfunction associated with corticosteroid use. A Phase 1 clinical formulation selection pharmacokinetic study of TNX-601 will be conducted outside of the U.S. in 2019. Tonix’s lead biologic candidate, TNX-801, is a potential smallpox-preventing vaccine based on a live synthetic version of horsepox virus, currently in the pre-IND application stage.
* TNX-102 SL (cyclobenzaprine HCl sublingual tablets) is an investigational new drug and has not been approved for any indication.
**Tonmya has been conditionally accepted by the U.S. Food and Drug Administration (FDA) as the proposed trade name for TNX-102 SL for the treatment of PTSD.
This press release and further information about Tonix can be found at http://www.tonixpharma.com.
Company Highlights:
Phase 3 development of new bedtime treatment for PTSD, including military related PTSD
Major unmet need; ~12 million Americans annually
Benefited from FDA 505(b)(2) NDA approval requirement
Complimentary day-time PTSD treatment in development
Leverages development expertise in PTSD, i.e., regulatory, trial recruitment and execution
Fibromyalgia bedtime treatment in development
New Phase 3 study design features discussed with FDA (April 2019 FDA Meeting Minutes)
TNX-102 SL 5.6 mg (twice the dose previously studied in FM Phase 2/3 trials) will be studied in Phase 3 to support the indication
New indication in development for agitation in Alzheimer’s Disease
Unmet medical need, no approved drug available
Fast Track Phase 2/3 ready program
Innovative vaccine in development to prevent Smallpox
Opportunity to supply stockpiling requirement; short development path
Studies in mice suggest improved safety profile
Recently Completed Milestones
July 2018 Completed P301/HONOR study interim analysis - result did not support study continuation but strengthened new Phase 3 study
August 2018 Presentation of P301/HONOR study results at Military Health System Scientific Symposium
October 2018 Met with FDA and received preliminary agreement on the design of new Phase 3 study of Tonmya for PTSD (P302/RECOVERY study)
November 2018 Received FDA minutes confirming agreement on the design of P302/RECOVERY study
March 2019 Met with FDA to discuss new FM Phase 3 study design using TNX-102 SL 5.6 mg
March 2019 P302/RECOVERY study initiated
April 2019 Received FDA formal minutes with clear guidance and support on new Phase 3 FM study
Upcoming Milestones
Second Half 2019 Preliminary human pharmacokinetic and safety data (non-IND study) from selected TNX-601 (tianeptine oxalate) formulation expected
First Half 2020 Topline data from P302/RECOVERY study expected
Market Outlook
Globally, the vast majority of people (~70%) will experience or witness one or more life-threatening traumatic events in their life-time. For many, the response to an isolated traumatic event will dissipate over days or a few weeks and have little or no long-term consequences.
For some individuals, however, the response to trauma will become chronic, lasting for more than one month and persisting for years, and, in many cases, decades. These individuals are considered to have PTSD and will experience psychiatric symptoms (flashbacks, intense anxiety and avoidance, emotional numbness, intense guilt or worry, agitation, sleep disturbances), and as a consequence, experience impaired social functioning, occupational disability, and an overall poor quality of life. PTSD is also characterized by overall high utilization of healthcare services, adding to the significant economic burden from the condition.
How prevalent is PTSD?
PTSD is a global problem, with the lifetime prevalence of PTSD estimated to be 3.9%, or affecting an estimated 200-300 million individuals, on a global basis.
Based on U.S. 12-month prevalence rates,1,2 it is estimated that about 11.0 million American adults suffer from DSM-5-defined PTSD in a given year. Similar to other psychiatric disorders, only approximately half of these individuals will seek treatment at some point in the course of the disease, and of these, approximately 40% (~1.8 million) will be formally diagnosed with PTSD in any given year. Lack of awareness, the negative stigma associated with PTSD (like other mental disorders), as well as the limitations of existing treatment options, may be addressed by increased societal awareness and acceptance as well as the introduction of new therapeutic options.
Technical Analysis
As we stated above, with its low-float of 4.74M, TNXP is no stranger to massive single-day run-ups.
TNXP's chart has recently formed a "Golden Cross" which generally signals an uptrend.
We've done our very own chart analysis, and see the potential for a move of over +27%!
The Bottom Line
We are extremely bullish on TNXP .
Based on our research we believe that this could be the biggest single-day gainer on the Nasdaq today.
That being said, we ask that you start your research on TNXP immediately and consider building a position this morning at 9:30AM EST
(*Remember to use a Stop-Loss Order or basic Limit Order to protect your gains, as well as limit possible losses.)
Best Regards,
The TopMarketGainers Team
Don't Miss Our Next Huge Winner...
Text 'GAINS' to '67076'
to have our Trade Alerts
Delivered Direct
to your Cell Phone.
(There is no charge.
Msg&data rates may apply.)
DISCLAIMER
This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned herewithin, nor intends to buy any in the future.
MJ Capital’s business model is to receive financial compensation to promote public companies. We have NOTbeen compensated to conduct investor relations advertising and marketing for TNXP . Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
$AMRH KEEP ON STRONG WATCH
****KEEP THIS NAME ON CLOSE WATCH, SPECULATION ON A GOOGLE PARTNERSHIP COMING TO FRUITION IS NOT BAKED INTO THE STOCK****
Earnings report Highlights
Revenues for the three months ended March 31, 2019 decreased by $0.38 million, or 3%, as compared to the three months ended March 31, 2018, mainly because we did not pursue certain low margin, professional services business during the three months ended March 31, 2019.
Our gross margin was 20% for the three months ended March 31, 2019, as compared to 21% for the three months ended March 31, 2018. The decrease in gross margin was due to one project related to solution based revenue which has lower margins, and no such revenue was applicable for the comparable period of 2018.
Our operating loss was $1.3 million for the three months ended March 31, 2019, as compared to $1.4 million for the three months ended March 31, 2018.
Our cash position was approximately $1.7 million as of March 31, 2019, as compared to $1.4 million as of December 31, 2018, an increase of approximately $0.3 million primarily due to the funds received from exercise of warrants.
We incurred recurring losses as a result of costs and expenses related to our selling, general and administration activities and acquisition strategy. As of March 31, 2019, we had negative working capital of $3.2 million and cash of $1.7 million. Historically, our principal sources of cash have included bank borrowings and sales of securities. Our operating expenses are likely to continue to grow and, as a result, we will need to generate significant additional revenues to cover such expenses.
$SMRT 45% JUMP TODAY ON AMAZON PARTNERSHIP
Stein Mart Inc . stock soared 45% in Tuesday trading after the off-price retailer announced that it will install Amazon Hub Lockers in nearly 200 stores in 28 states. Amazon Lockers are found in various other locations including NYSE:KSS . This is a superb opportunity to increase footfall into the stores without any marketing expenses. It is also interesting to see the option activity with a high quantity of $2 call traded, this is indeed very bullish , options are often a very good read on what is ahead.
For a safe entry point it is advisable to wait for a break above the 200 day MA and the downtrend line(blue).
$SMRT 45% JUMP TODAY ON AMAZON PARTNERSHIP
Stein Mart Inc . stock soared 45% in Tuesday trading after the off-price retailer announced that it will install Amazon Hub Lockers in nearly 200 stores in 28 states. Amazon Lockers are found in various other locations including NYSE:KSS . This is a superb opportunity to increase footfall into the stores without any marketing expenses. It is also interesting to see the option activity with a high quantity of $2 call traded, this is indeed very bullish , options are often a very good read on what is ahead.
For a safe entry point it is advisable to wait for a break above the 200 day MA and the downtrend line(blue).
$OBLN OBALON THERAPEUTICS crazy move tomorrow UP 58% afterhours
************************STRONG WATCH FOR TOMORROW, BREAK ABOVE $.65 WILL BE BRING A MASSIVE RALLY, UP 58% afterhours*****************
ANALYSTS AVERAGE RECOMMENDATION OVERWEIGHT
ANALYSTS AVERAGE PRICE TARGET $1.83
OBALON THERAPEUTICS INC.
Obalon Therapeutics, Inc. focuses on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. Its product includes medical balloon technology for weight loss therapy which consists of a capsule containing a balloon that is swallowed and then remotely inflated.
$OBLN OBALON THERAPEUTICS crazy move tomorrow UP 58% afterhours
************************STRONG WATCH FOR TOMORROW, BREAK ABOVE $.65 WILL BE BRING A MASSIVE RALLY, UP 58% afterhours*****************
ANALYSTS AVERAGE RECOMMENDATION OVERWEIGHT
ANALYSTS AVERAGE PRICE TARGET $1.83
OBALON THERAPEUTICS INC.
Obalon Therapeutics, Inc. focuses on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. Its product includes medical balloon technology for weight loss therapy which consists of a capsule containing a balloon that is swallowed and then remotely inflated.
$LOW HAS HOME DEPOT LOWERED EXPECTATIONS FOR LOWE'S?
Dependant on your perspective the chart of NYSE:LOW could be interpreted as bullish or bearish . Many of the indicators are positive but that may be offset by market sentiment in the retail sector. Home depot reported today and it was not exactly a blowout quarter, with as expected weather issues interfering with sales. Lumber prices were also an issue and that will be no different for Lowes. It is indeed difficult to make any trading decisions in the current market with such volatility but we believe that the correction in NYSE:LOW has a little further to go.
We have no position and will not make any call either way until after earnings but there is plenty of time to get involved.
$LOW HAS HOME DEPOT LOWERED EXPECTATIONS FOR LOWE'S?
Dependant on your perspective the chart of NYSE:LOW could be interpreted as bullish or bearish . Many of the indicators are positive but that may be offset by market sentiment in the retail sector. Home depot reported today and it was not exactly a blowout quarter, with as expected weather issues interfering with sales. Lumber prices were also an issue and that will be no different for Lowes. It is indeed difficult to make any trading decisions in the current market with such volatility but we believe that the correction in NYSE:LOW has a little further to go.
We have no position and will not make any call either way until after earnings but there is plenty of time to get involved.
$LOW HAS HOME DEPOT LOWERED EXPECTATIONS FOR LOWE'S?
Dependant on your perspective the chart of NYSE:LOW could be interpreted as bullish or bearish . Many of the indicators are positive but that may be offset by market sentiment in the retail sector. Home depot reported today and it was not exactly a blowout quarter, with as expected weather issues interfering with sales. Lumber prices were also an issue and that will be no different for Lowes. It is indeed difficult to make any trading decisions in the current market with such volatility but we believe that the correction in NYSE:LOW has a little further to go.
We have no position and will not make any call either way until after earnings but there is plenty of time to get involved.
$AAP Advance Auto carries good momentum into earnings
Todays earnings report from NYSE:AZO was bullish as we expected and the stock has moved considerably higher, our expectations are very much the same for NYSE:AAP whom report tomorrow before the bell. In our last analysis we had hoped for a breakout above $183 which failed but this remains our breakout level which will soon be tested once again. Despite falling below the crucial MA's support the stock is rallying once again on high volume with a nice reset in the RSI and Stoch , they MACD is negative but a cross is imminent.
This we think is a long term winner and a pretty secure long into earnings
$AAP Advance Auto carries good momentum into earnings
Todays earnings report from NYSE:AZO was bullish as we expected and the stock has moved considerably higher, our expectations are very much the same for NYSE:AAP whom report tomorrow before the bell. In our last analysis we had hoped for a breakout above $183 which failed but this remains our breakout level which will soon be tested once again. Despite falling below the crucial MA's support the stock is rallying once again on high volume with a nice reset in the RSI and Stoch , they MACD is negative but a cross is imminent.
This we think is a long term winner and a pretty secure long into earnings
$URBN OPTIONS ACTIVITY POINTS TO $23 ON THE DOWNSIDE
retail WRECKAGE HAS ENSUED TODAY AND IN OUR OPINION THAT WILL CONTINUE INTO THE EARNINGS REPORT FROM NASDAQ:URBN . ALREADY IN A MASSIVE DOWNTREND THE OPTIONS MARKET HAS BEEN ACTIVE WITH THE $23 PUTS STRIKE EXPIRING ON MAY 24TH . THEY STOCK HAS ALREADY LOST STRONG SUPPORT AT $27 NEXT STOP IS $23, $22 THEN $16. CURRENT SHORT INTEREST IS 16% AND WE EXPECT THAT TO INCREASE.
AVERAGE RECOMMENDATION OVERWEIGHT
AVERAGE PRICE TARGET $35
$URBN OPTIONS ACTIVITY POINTS TO $23 ON THE DOWNSIDE
retail WRECKAGE HAS ENSUED TODAY AND IN OUR OPINION THAT WILL CONTINUE INTO THE EARNINGS REPORT FROM NASDAQ:URBN . ALREADY IN A MASSIVE DOWNTREND THE OPTIONS MARKET HAS BEEN ACTIVE WITH THE $23 PUTS STRIKE EXPIRING ON MAY 24TH . THEY STOCK HAS ALREADY LOST STRONG SUPPORT AT $27 NEXT STOP IS $23, $22 THEN $16. CURRENT SHORT INTEREST IS 16% AND WE EXPECT THAT TO INCREASE.
AVERAGE RECOMMENDATION OVERWEIGHT
AVERAGE PRICE TARGET $35
$TGT Bullish and bearish Count in Target
Target earnings is going to be very interesting for the broader market as NYSE:WMT NYSE:HD NYSE:KSS have all disappointing investors.
We have included two scenarios for Target post earnings tomorrow but our bias is on the bearish side. It is our belief that retail is suffering once again and sentiment is quite poor in the segment. They MA'S are very bearish and are holding down the price. A test of the December lows in the $60 range is our minimum target for the C wave with $54 a very bearish target.
$TGT Bullish and bearish Count in Target
Target earnings is going to be very interesting for the broader market as NYSE:WMT NYSE:HD NYSE:KSS have all disappointing investors.
We have included two scenarios for Target post earnings tomorrow but our bias is on the bearish side. It is our belief that retail is suffering once again and sentiment is quite poor in the segment. They MA'S are very bearish and are holding down the price. A test of the December lows in the $60 range is our minimum target for the C wave with $54 a very bearish target.
$TOL BULLISH SET UP INTO EARNINGS
Despite the fact that analysts are less than bullish on the stock, we have confidence that a good report will follow on from the rising home sales figures released last month. Toll brothers stock has suffered a deep correction from 2018 highs, but is now in a well defined uptrend with out target in the $43 region. Within the chart there is a possibility of a inverse H&S forming, with the price sitting on support a volume spike could validate the setup.
Given the fact that analysts are skeptical, a good earnings report could result in upgrades and a short squeeze in the days and weeks to follow.
$TOL BULLISH SET UP INTO EARNINGS
Despite the fact that analysts are less than bullish on the stock, we have confidence that a good report will follow on from the rising home sales figures released last month. Toll brothers stock has suffered a deep correction from 2018 highs, but is now in a well defined uptrend with out target in the $43 region. Within the chart there is a possibility of a inverse H&S forming, with the price sitting on support a volume spike could validate the setup.
Given the fact that analysts are skeptical, a good earnings report could result in upgrades and a short squeeze in the days and weeks to follow.